Skip to main content

View full-text article in PMC

. 2022 Sep 1;14(9):e28683. doi: 10.7759/cureus.28683

Table 5. Sub-group analysis of patients in duloxetine group.

BMI: body mass index; HbA1c: glycated hemoglobin

Parameters		Efficacy		Total	p value
Parameters		Yes	No	Total	p value
Age	30-45 years	12 (85.7%)	02 (14.3%)	14 (100.0%)	0.877
	46-60 years	15 (78.9%)	04 (21.1%)	19 (100.0%)
	61-80 years	08 (80.0%)	02 (20.0%)	10 (100.0%)
Gender	male	25 (86.2%)	04 (13.8%)	29 (100.0%)	0.243
Gender	female	10 (71.4%)	04 (28.6%)	14 (100.0%)	0.243
Disease duration	Less than 20 months	21 (87.5%)	03 (12.5%)	24 (100.0%)	0.247
Disease duration	More than 20 months	14 (73.7%)	05 (26.3%)	19 (100.0%)	0.247
HbA1c	≤8%	09 (69.2%)	04 (30.8%)	13 (100.0%)	0.177
HbA1c	>8%	26 (86.6%)	04 (13.1%)	30 (100.0%)	0.177
BMI	≤23Kg/m²	21 (84.0%)	04 (16.0%)	25 (100.0%)	0.604
BMI	>23kg/m²	14 (77.7%)	04 (22.3%)	18 (100.0%)	0.604